أدوية GLP-1 تعيد تشكيل معرفتنا بالإدمان والزهايمر وأمراض القلب

When GLP-1 receptor agonists were first approved for type 2 diabetes, the mechanism was well understood: the drugs mimic a gut hormone that stimulates insulin release and slows gastric emptying. What nobody fully anticipated was what happened when these same receptors were activated in the brain. The weight loss was striking. But it was the signals coming from unexpected corners of medicine -- addiction clinics, neurology wards, cardiology units -- that have turned GLP-1 drugs into one of the most broadly consequential drug classes in recent memory.

Quieting the Craving: Addiction Research

The largest study yet on GLP-1 drugs and addiction, published in The BMJ in March 2026, analyzed over 600,000 U.S. veterans. The findings were striking: patients taking GLP-1 medications showed a reduced risk of developing substance use disorders across every major addictive substance tested -- alcohol, cannabis, cocaine, nicotine, and opioids. Among patients already diagnosed with a substance use disorder, the drugs were associated with fewer hospitalizations, fewer emergency department visits, fewer overdoses, and fewer drug-related deaths.

The proposed mechanism mirrors what the drugs do with food: GLP-1 receptors in the reward circuits of the brain appear to reduce what researchers call "drug noise" -- the persistent background craving that makes abstinence so difficult to maintain. A separate clinical trial reported in May 2026 specifically tested semaglutide in patients with alcohol use disorder and found a significant reduction in alcohol consumption. The implication is that the same neural pathway that drives compulsive eating may overlap substantially with the pathways that drive compulsive drug use. If confirmed in larger trials, this would represent a fundamental insight into the neuroscience of addiction -- and a new class of treatment.

The Alzheimer's Question

The results on Alzheimer's disease have been more mixed, and more carefully watched than perhaps any other application. A major trial by Novo Nordisk testing an oral form of semaglutide in patients with early Alzheimer's -- the EVOKE studies -- did not show a statistically significant slowing of disease progression. That was a disappointing result for a research community that had been cautiously optimistic.

But a separate trial led by Imperial College London, testing a different GLP-1 drug, liraglutide, published in Nature, told a different story: nearly 50% less brain volume loss and an 18% slower decline in cognitive function compared to placebo. The discrepancy between the two trials has generated significant scientific debate, with some researchers suggesting the difference may lie in which GLP-1 receptor subtypes the two drugs activate, or in the patient populations studied.

The theoretical case for GLP-1 drugs in Alzheimer's remains compelling regardless. They reduce neuroinflammation, improve brain insulin sensitivity -- a known factor in cognitive decline -- and appear to help clear toxic protein aggregates. Observational studies consistently show that patients taking GLP-1 medications have lower rates of cognitive decline. The field is not ready to recommend them for Alzheimer's prevention, but the University of Cincinnati's ongoing analysis of real-world patient data and multiple other trials in progress will clarify the picture considerably over the next two years.

Cardiovascular: The Clearest Evidence

The cardiovascular evidence is the most robust. A large international review published in May 2026, covering over 90,000 patients, found that GLP-1 drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term -- independent of whether the patient has diabetes. The reduction in major adverse cardiovascular events was approximately 13%.

Research from the University of Bristol and University College London, published in Nature Communications in March 2026, identified a specific mechanism: GLP-1 drugs appear to prevent further tissue damage following a heart attack by improving blood flow in narrowed coronary capillaries. This suggests the drugs are not only protective before cardiac events but may limit damage after them.

One important caveat emerged from a BMJ Medicine study: the cardiovascular benefits diminish if treatment is discontinued. Heart risks begin rising again within six months of stopping the drug, and much of the benefit fades within about 18 months. This has implications for how physicians and payers think about these drugs -- as chronic, ongoing treatments rather than courses of therapy.

New Formulations and the Next Generation

The practical accessibility of GLP-1 therapy is also changing. An oral form of semaglutide (Wegovy) launched in the United States in January 2026, removing the injection barrier that has kept many patients from considering the drugs. A second oral GLP-1, orforglipron (Foundayo), was approved by the FDA in April 2026, notable for having none of the strict food and water restrictions that complicate the other oral options.

Looking slightly further ahead, a new class of drugs targeting multiple hormone pathways simultaneously -- combining GLP-1 with GIP, glucagon, or amylin receptors -- is in final-stage testing. Early results suggest even greater therapeutic effects than current single-agonist drugs, both for weight and for the broader metabolic and neurological effects now being documented. These are expected to reach regulators in late 2026 or 2027.

The Broader Implication

What the expanding GLP-1 evidence base reveals is a drug class that happened to target a receptor system that turns out to be involved in a much wider range of human pathology than anyone initially appreciated. The gut-brain axis -- long known to regulate appetite -- also appears to modulate addiction, neuroinflammation, cardiac repair, and metabolic function in ways that researchers are still mapping. GLP-1 drugs became important because they worked for diabetes and obesity. They may become transformative because of what they revealed about how the body regulates itself.